论文部分内容阅读
目的探讨改良B-NHL-BFM95方案治疗儿童非霍奇金淋巴瘤的临床疗效和毒副反应。方法入组20例经病理确诊的14岁以下非霍奇金淋巴瘤患者,均接受改良B-NHL-BFM95方案治疗,未行放疗。结果近期疗效:18例(90.0%)CR,2例(10.0%)PD。治疗期间大部分患者出现Ⅲ、Ⅳ度骨髓抑制,经对症处理恢复正常,不影响下一步治疗。中位随访55个月,全组3 a无事件生存率80.0%,Ⅰ~Ⅱ期100.0%,Ⅲ~Ⅳ期60.0%;低危组100.0%,中危组85.7%,高危组50.0%。结论改良B-NHL-BFM-95方案治疗儿童非霍奇金淋巴瘤,特别是低、中危儿童非霍奇金淋巴瘤疗效显著,毒副反应可耐受。
Objective To investigate the clinical efficacy and toxicity of modified B-NHL-BFM95 regimen in children with non-Hodgkin’s lymphoma. Methods Twenty patients with non-Hodgkin’s lymphoma under 14 years of age who were confirmed by pathology were enrolled in the modified B-NHL-BFM95 regimen without radiotherapy. The results of the recent curative effect: 18 cases (90.0%) CR, 2 cases (10.0%) PD. During the treatment of most patients with Ⅲ, Ⅳ degree myelosuppression, symptomatic treatment returned to normal, does not affect the next step of treatment. The median follow-up was 55 months. The 3-year event-free survival rate was 80.0%, 100.0% for stage Ⅰ-Ⅱ, 60.0% for stage Ⅲ-Ⅳ, 100.0% for low-risk group, 85.7% for intermediate-risk group and 50.0% for high-risk group. Conclusion The modified B-NHL-BFM-95 regimen is effective in treating children with non-Hodgkin’s lymphoma, especially in children with low or intermediate risk.